Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Short Interest Down 30.7% in August

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLEGet Rating) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totalling 810,500 shares, a drop of 30.7% from the August 15th total of 1,170,000 shares. Based on an average daily volume of 2,090,000 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analyst Weigh In

AGLE has been the subject of several research analyst reports. Jonestrading reaffirmed a “buy” rating and set a $3.00 target price on shares of Aeglea BioTherapeutics in a research note on Thursday, August 25th. Needham & Company LLC lowered shares of Aeglea BioTherapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, June 2nd. StockNews.com started coverage on shares of Aeglea BioTherapeutics in a research note on Thursday. They issued a “hold” rating for the company. Wells Fargo & Company cut their price objective on shares of Aeglea BioTherapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Tuesday, August 9th. Finally, Piper Sandler cut shares of Aeglea BioTherapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $4.00 to $1.00 in a report on Thursday, June 2nd. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Aeglea BioTherapeutics has a consensus rating of “Hold” and a consensus price target of $1.63.

Insider Buying and Selling at Aeglea BioTherapeutics

In other Aeglea BioTherapeutics news, Director Marcio Souza bought 90,000 shares of Aeglea BioTherapeutics stock in a transaction dated Thursday, August 25th. The stock was acquired at an average cost of $0.56 per share, for a total transaction of $50,400.00. Following the completion of the transaction, the director now directly owns 90,000 shares of the company’s stock, valued at $50,400. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Aeglea BioTherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in AGLE. Dimensional Fund Advisors LP boosted its position in shares of Aeglea BioTherapeutics by 9.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 690,573 shares of the biotechnology company’s stock worth $3,279,000 after buying an additional 57,740 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Aeglea BioTherapeutics in the 4th quarter valued at about $620,000. ClariVest Asset Management LLC acquired a new position in Aeglea BioTherapeutics in the 4th quarter valued at about $832,000. Blair William & Co. IL raised its stake in Aeglea BioTherapeutics by 46.7% in the 4th quarter. Blair William & Co. IL now owns 76,594 shares of the biotechnology company’s stock valued at $364,000 after purchasing an additional 24,390 shares during the last quarter. Finally, Sio Capital Management LLC raised its stake in Aeglea BioTherapeutics by 11.8% in the 4th quarter. Sio Capital Management LLC now owns 498,500 shares of the biotechnology company’s stock valued at $2,368,000 after purchasing an additional 52,500 shares during the last quarter. 81.03% of the stock is currently owned by hedge funds and other institutional investors.

Aeglea BioTherapeutics Stock Performance

Shares of NASDAQ AGLE opened at $0.53 on Friday. The firm has a market capitalization of $32.43 million, a P/E ratio of -0.42 and a beta of 1.66. Aeglea BioTherapeutics has a one year low of $0.37 and a one year high of $8.50. The company’s fifty day moving average is $0.50 and its two-hundred day moving average is $1.22.

Aeglea BioTherapeutics (NASDAQ:AGLEGet Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.01). Aeglea BioTherapeutics had a negative return on equity of 105.49% and a negative net margin of 1,244.84%. The company had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $1.42 million. On average, sell-side analysts forecast that Aeglea BioTherapeutics will post -1.09 earnings per share for the current fiscal year.

Aeglea BioTherapeutics Company Profile

(Get Rating)

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.

Recommended Stories

Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.